BIT — Biotron Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- AU$42.12m
- AU$39.86m
- AU$1.46m
- 40
- 12
- 40
- 21
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 21.77 | ||
| Price to Tang. Book | 21.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -135.91% | ||
| Return on Equity | -83.21% | ||
| Operating Margin | -193.77% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.66 | 1.62 | 1.07 | 0.8 | 1.46 | n/a | n/a | -1.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotron Limited is a biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. It is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The Company's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The Company progresses its Hepatitis B virus (HBV) program. It also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
Directors
- Michael Hoy NEC
- Michelle Miller CEO
- Stephen Becker OTH
- Peter Nightingale SEC
- Stephen Locarnini DRC
- Susan Pond NID
- Robert Thomas NID (75)
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- February 23rd, 1999
- Public Since
- January 24th, 2001
- No. of Shareholders
- 6,709
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 701,932,713
- Address
- Suite 3.3, 56 Delhi Road, NORTH RYDE, 2113
- Web
- http://www.biotron.com.au/
- Phone
- +61 298050488
- Auditors
- KPMG
Upcoming Events for BIT
Biotron Ltd Annual Shareholders Meeting
Similar to BIT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
FAQ
What is the Biotron share price?
As of Today at 13:03 UTC, shares in Biotron are trading at AU$0.06. This share price information is delayed by 15 minutes.
How has the Biotron share price performed this year?
Shares in Biotron last closed at AU$0.06 and the price had moved by +23.08% over the past 365 days. In terms of relative price strength the Biotron share price has outperformed the ASX All Ordinaries Index by +39.46% over the past year.
What are the analyst and broker recommendations for Biotron?
There is no consensus recommendation for this security.
What is the Biotron dividend yield?
Biotron does not currently pay a dividend.
Does Biotron pay a dividend?
Biotron does not currently pay a dividend.
When does Biotron next pay dividends?
Biotron does not currently pay a dividend.
How do I buy Biotron shares?
To buy shares in Biotron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biotron?
As of the previous close price of AU$0.06, shares in Biotron had a market capitalisation of AU$42.12m.
Where are Biotron shares listed?
Here are the trading details for Biotron:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BIT
What kind of share is Biotron?
Based on an overall assessment of its quality, value and momentum Biotron is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biotron share price forecast for 2022?
We could not find analyst target price data for this security.
What is the trend in the Biotron share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotron. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -21.31%.
As of the last closing price of AU$0.06, shares in Biotron were trading -16.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biotron PE Ratio?
The Biotron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biotron?
Biotron's management team is headed by:
- Michael Hoy - NEC
- Michelle Miller - CEO
- Stephen Becker - OTH
- Peter Nightingale - SEC
- Stephen Locarnini - DRC
- Susan Pond - NID
- Robert Thomas - NID